PLANO, Texas, Dec. 13, 2013 /PRNewswire/ -- Assured Pharmacy, Inc. (OTCQB: APHY), today announced that it has extended the expiration of its previously announced tender offer to exchange 16% Senior Convertible Debentures (the "Eligible Debentures") and warrants to purchase common stock (the "Eligible Warrants") (collectively the "Eligible Securities") for either:
Option #1: The issuance of restricted shares of common stock for the settlement of the balance of the Eligible Debenture, which shall consist of principle plus the currently outstanding unpaid interest as of September 30, 2013, at $0.60 per share with the issuance of new warrants to purchase common stock (the "New Warrants") at an exercise price of $0.60 per share for the first twelve (12) months following the closing date of the issuer tender offer (the "Tender Offer") and $0.75 thereafter for the remainder of the New Warrant's term, with such term to be an extension of the term of the Eligible Warrant by an additional three (3) years, or
Option #2: The issuance of amended and restated debentures (the "New Debentures") which include the principal balance plus all accrued and unpaid interest as of September 30, 2013 of the Eligible Debentures with a reduction of the interest rate from sixteen percent (16%) to ten percent (10%), the extension of the maturity date for an additional three (3) years past the Eligible Debenture's maturity date, reduction of the conversion price to $0.75 per share, and execution of a subordination agreement pursuant to which the Company will make no further payments to the debt holders until such time as the redemption of certain Series D Preferred Stock (to be designated) has been made in full ("Subordination Agreement") and the issuance of New Warrants, the expiration date of which shall be 3 years past the expiration date set forth in the Eligible Warrants and a reduction of the conversion price to $0.75 per share.
The issuer tender offer was previously set to expire at 11:59 P.M. (Eastern time) on Friday, December 13, 2013 and will now expire at 11:59 P.M. (Eastern time) on Tuesday, December 31, 2014 unless further extended or terminated. Issuer Direct, LLC, the Company's tender offer agent has advised that Elections to Participate and Notice of Conversions representing approximately $965,784 of principal of the Eligible Debentures have been received.Important Notice This press release is for informational purposes only and is neither an offer to exchange nor a solicitation of an offer to exchange any of the company's securities. The offer to exchange will be made only pursuant to the Offer to Exchange, the related election to participate, notice of conversion and other materials that have been mailed to holders of securities eligible to be exchanged in the offer and have been filed with the SEC. Holders of securities eligible to be exchanged in the offer should read those materials and the documents incorporated therein by reference carefully because they contain important information, including the various terms of, and conditions to, the exchange offer. The Company has filed a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission, which includes the Offer to Exchange, the related election to participate and other materials, and is available at no charge at the Securities and Exchange Commission's website at www.sec.gov, or from the Company's tender offer agent, Issuer Direct at 500 Perimeter Park Drive, Suite D, Morrisville, NC 27560 telephone (866) 752-8683. Holders of securities eligible to be exchanged in the offer are urged to read those materials carefully prior to making any decisions with respect to the exchange offer. About Assured Pharmacy, Inc. Assured Pharmacy, Inc. (the "Company") is a growing chain of specialty pharmacies that provide advanced prescription services to a diverse array of medical professionals and their patients. Assured Pharmacy is committed to providing these physicians and patients with a better prescription process. This enhanced process is achieved by blending advanced prescribing technologies with focused pharmacology.